Hereditary Breast and Ovarian Cancer (HBOC)
Test 2.
Large deletion/insertion rearrangements in the BRCA1 gene
Test 3.
Large deletion/insertion rearrangements in the BRCA2 gene
Hereditary Nonpolyposis Colorectal Cancer HNPCC (Lynch syndrome)
Test 5.
Microsatellite instability of a panel of 10 markers (normal sample/tumor)
Test 6.
Mutations in 38 colorectal cancer associated genes
Test 7.
HNPCC (Lynch syndrome) - Mutations in MLH1 gene
Test 8.
HNPCC (Lynch syndrome) - Mutations in MSH2 gene
Test 9.
HNPCC (Lynch syndrome) - Mutations in MSH6 gene
Test 10.
Large deletions/ insertions and rearrangements in MLH1 and MSH2 genes
Test 11.
A panel of 5 genes associated with HNPCC
Hereditary Gastrointestinal Tumors
Test 12.
Mutation in 43 associated genes with hereditary gastrointestinal tumors, colorectal and stomac cancer or polyps developmental risk
Familial adenomatous polyposis (FAP)
Test 16.
Large deletions/ insertions and rearrangements in APC gene
Hirschsprung's disease
Multiple Endocrine Neoplasia (MEN)
Test 19.
Mutations in exons 10, 11, 13, 14, 15, 16 of RET gene (covering 90% of the known mutations)
Test 20.
Mutations in all exons of RET gene (excluding exons 10, 11, 13, 14, 15, 16)
Li-Fraumeni syndrome
Familial prostate cancer
Familial pancreatic cancer
Test 25.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с рак на панкреаса
Фамилен рак на кожата
Test 26.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с рак на кожата
Наследствени онкологични заболявания
Test 27.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с наследствени онкологични заболявания
Hematologic Oncologic Diseases
Hereditary Paraganglioma / Pheochromocytoma / PGL / PCC syndrome
Test 28.
Mutations in 20 genes associated with Hereditary Paraganglioma/ Pheochromocytoma
Hereditary syndromes associated with tumors of the CNS, PNS
Test 29.
Mutations in 36 genes associated with CNS/ PNS tumors
RASopathies, Genetic syndromes resulting of mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway
Test 30.
Mutations in 36 panel genes
Мedulloblastoma
Sarcoma
Childhood solid tumors (Neublastom / rhabdomyosarcoma / Ewing's sarcoma / Wilm's tumor)
Hereditary Neuroblastoma
Test 31.
Mutation in 2 associated with hereditary neuroblastoma gene panel (ALK and PHOX2B)
Neurofibromatosis type 1
Test 33.
Analysis of the NF1 gene for large deletions / insertions and rearrangements
Neurofibromatosis type 2
Test 34.
Analysis of the NF2 gene for large deletions / insertions and rearrangements
Gorlin Goltz syndrome
Test 36.
Mutations in exons 1, 4, 5, 7, 11, 12, 14, 16, 17, 18, 19, 20, 21 22, 23 of PTCH1 gene
Tuberous sclerosis
Test 38.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с туберозна склероза
Epilepsy with febrile seizures, GEFS + and Dravet syndrome
Test 40.
Deletions/duplications and rearrangements of SCN1A gene
Test 41.
Mutations, deletions/duplications and rearrangements in SCN1A gene
Epilepsy with benign neonatal and neonatal-infantile seizures and early onset epileptic encephalopathy
Test 42.
Mutations in KCNQ2 gene
Test 43.
Deletions/duplications and rearrangements of KCNQ2 gene
Test 44.
Mutations, deletions/duplications and rearrangements of KCNQ2 gene
Childhood absence epilepsy and GLUT1 deficiency
Test 46.
Deletions/duplications and rearrangements in SLC2A1(GLUT1) gene
Test 47.
Mutations and deletions/duplications and rearrangements in SLC2A1(GLUT1) gene
Epileptic encephalopathies
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
Test 49.
Mutation in 84 autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) genes
Epilepsy and epileptic syndromes - extended panel
Test 50.
Mutations in 1089 epilepsy and epileptic syndromes associated genes
Мigraine
Neuromuscular diseases
Congenital hypotension
Test 53.
Mutations in 2981 genes, associated with genetic diseases of the CNS and peripheral neuropathies in childhood
Hereditary spastic paraplegia
Test 55.
Големи делеции/инсерции и/или пренареждания в SPAST (SPG4) и ATL1 гените
Test 56.
Mutations in 111 hereditary spastic paraplegia associated genes
Hereditary spastic paraplegia, a recessive form associated with cerebellar ataxia
Test 57.
Hotspot mutation p.L78X in SPG7 gene
Hereditary Motor-Sensory Neuropathies
Test 58.
Mutations in 281 genes associated with hereditary motor and sensory neuropathies
Hereditary Ataxias
Test 59.
Mutations in 661 genes associated with ataxia and syndromes and diseases, which include symptoms of ataxia
Cerebellar hypoplasia
Syndromic intellectual deficit and neurodevelopmental disorders
Test 61.
Mutations in 3123 genes associated with intellectual deficit and neuropsychiatric retardation
Autism
Developmental delay, intellectual disability, and/or congenital anomalies
Test 63.
Субтеломерни микроделеции/микродупликации, свързани с изоставане в умственото развитие
Known microdeletion/microduplication syndromes
Test 64.
Големи делеции/инсерции пренареждания в целия геном, свързани с известни микроделеционни/микродупликационни синдроми
Alzheimer's disease
Parkinson's disease
Dementia
Frontotemporal degeneration
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis/ Frontotemporal degeneration
Test 71.
Copy number varioations in C9orf72
Motor disorders
Test 72.
Mutations in 1360 genes associated with chorea, dystonia and other movement disorders
Leukodystrophy with childhood-onset
Test 73.
Mutations in 2938 genes associated with childhood onset leukodystrophy
Leukodystrophy with brain calcifications
Test 74.
Mutations in 232 genes associated with leukodystrophy with brain calcifications
Leukodystrophy with late-onset
Macular degeneration
Test 76.
Mutations in ABCA4 gene- coding and non-coding regions
Test 77.
Large deletions/insertions in the ABCA4 gene
Test 78.
Mutations in a panel of 14 genes associated with Stargardt disease
Test 79.
Mutations in BEST1 gene
Test 80.
Mutations in a panel of 30 genes associated with macular degeneration
Glaucoma
Cone-rod retinal degeneration
Test 85.
Mutations in CRX and GUCY2D genes and exon 15 in RPGR-ORF15 gene
Test 88.
Mutations in 42 genes, associated with cone-rod retinal degeneration
Leber hereditary optic neuropathy
Test 92.
Mutations in 3 mitochondrial genes- MT-ND1, MT-ND4 и MT-ND6
Retinal pigment degeneration
Test 93.
Mutations in RHO, PRPH2/RDS, PRPF31 and IMPDH1 genes and exon 15 in RPGR-ORF15 gene
Test 94.
Mutations in USH2A, CRB1 и RHO genes and exon 15 in RPGR-ORF15 gene
Test 98.
Large deletions/insertions in the RHO, IMPDH1, RP1 and PRPF31 genes
Test 99.
Large deletions/insertions in the USH2A
Test 100.
Large deletions/insertions in EYS gene
Test 101.
Mutations in 341 genes, associated with Retinitis pigmentosa
Usher syndrome type 2
Test 102.
Mutations in 341 genes assotiated with retinal degeneration
Bardet-Biedl syndrome
Congenital stationary night blindness
Test 106.
Mutations in 14 genes associated with Congenital stationary night blindness
Retinoschisis
Retinoblastoma
Cataract
Hereditary and sporadic nonsyndromic neurosensory hearing loss
Test 111.
Mutations in GJB2(Cx26) gene
Test 112.
Mutations in GJB3 (Cx31) gene
Test 113.
Mutations in 4 mitochondrial genes- MT-RNR1, MT-TS1 , MT-TL1 , MT-TK
Test 114.
Mutations in 594 genes associated with hearing loss
Syndromic and non-syndromic hearing loss
Sensorineural hearing loss and Wolfram syndrome type 1
Test 115.
Large deletions and duplications in GJB2, GJB3, GJB6, WFS1, POU3F4 and detection of 6 mutations in GJB2 гена (c.313del14, c.235delC, c.167delT, c.101T>C, c.35delG и IVS1+1G>A)
Cortico-resistant nephrotic syndrome
Test 116.
Screening for mutations in the coding regions of NHPS1 and NPHS2 genes as well as exons 8 and 9 of WT1 gene
Test 117.
mutations in 26 genes associated with nephrotic syndrome
Congenital anomalies of the urinary system
Test 118.
Screening for mutations in the coding regions of HNF1B and PAX2 genes
Test 119.
Screening for mutations in the coding regions of 214 CAKUT associated genes
Test 120.
Screening for large deletions/duplications affecting the HNF1B gene
UMOD-associated nephropathy
Ciliopathies
Hereditary kidney diseases
Test 123.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с наследствени бъбречни заболявания
Endocrine diseases
Congenital hypopituitarism
Congenital hypothyroidism
Test 128.
Large deletions/ insertions and rearrangements in TPO, PAX8, FOXE1, NKX2-1 и TSHR genes
Isolated growth hormone deficiency
Maturity-onset diabetes of the young (MODY)
Test 131.
Large deletions/ insertions and rearrangements in HNF4A, GCK, HNF1A and HNF1B genes
Cardiomyopathies and arrhythmias
Test 135.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с кардиомиопатии и аритмии
Familial hypercholesterolemia
Test 136.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с фамилна хиперхолестеролемия
Familial hypertriglyceridemia
Test 137.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с фамилна хипертриглицеридемия
Familial lipodystrophy
Test 138.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с фамилна липодистрофия
Familial disorders associated with an increased risk of cerebrovascular events (stroke)
Test 139.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с Фамилни заболявания с повишен риск за цереброваскуларен инцидент (инсулт)
Ehlers–Danlos syndrome and related disorders
Test 140.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани със Синдром на Ehler-Danlos и свързани заболявания
Familial hemorrhagic telangiectasia and vascular malformations
Test 141.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с фамилна хеморагична телангиектазия и васкуларни малформации
Familial heart diseases
Test 142.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с фамилна изолирано или синдромно вродено сърдечно заболяване
Cardiological diseases
Mitochondrial diseases
Test 143.
Mutations in 37 mitochondial genes associated with mitochondrial diseases
Test 144.
Mutations in 266 nuclear genes associated with mitochondrial diseases
Connective tissue diseases
Marfan syndrome and Marfan-like diseases
Test 148.
Големи делеции/инсерции пренареждания в FBN1 генa
Skeletal dysplasias
Multiple congenital malformation disorders
Test 150.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с мулти малформативни заболявания
Arthrogryposis
Monogenic inflammatory bowel diseases (IBD) with early onset (before 6 years of age)
Test 152.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с IBD с ранно начало
Familial pancreatitis
Test 153.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с Фамилен панкреатит
Hirschsprung disease
Test 154.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с Болест на Hirschsprung
Liver diseases
Immune diseases
Hematological diseases
Syndromic and non-syndromic diseases with dermatological symptoms
Test 158.
Mutations in panel of 423 genes
Reproductive panel - women
Reproductive panel - men
Carrier screening for heterozygous carriers of recessive diseases in couples
Test 162.
Цялостно екзомно секвениране (WES) и анализ на панел от гени, асоциирани с рецесивни заболявания
Metabolic diseases
BRCA-related expanded panel for assessment of familial risk and therapy selection
Test 165.
Анализ на BRCA1, BRCA2, CHEK2, PALB2, RAD51C и TP53 гените
Therapy selection in breast cancer
Therapy selection in prostate cancer
Test 168.
Таргетно секвениране на панел от HRR гени за установяване на варианти свързани с дефицит на хомоложна рекомбинация (HRD)
Therapy selection for solid tumors associated with homologous recombination deficiency (breast, ovarian, prostate, and pancreatic cancers)
Test 169.
Установяване на дефицит на хомоложна рекомбинация (HRD)
Comprehensive genomic profiling (CGP) for therapy selection in solid tumors
Test 170.
Анализ на соматични ДНК варианти в панел от гени* (SNVs, InDels,SVs, CNVs), генни фузии и сплайс варианти на РНК ниво, определяне на дефицит на хомоложна рекомбинация (HRD), микросателитна нестабилност (MSI), туморен мутационен товар (TMB)
Targeted gene panel sequencing for solid tumors for therapy selection
Test 171.
Анализ на соматични ДНК варианти (SNVs, InDels,SVs, CNVs) в панел от 95 гени при солидни тумори
Prognostic markers in tumors of the central nervous system
Test 172.
mutaions in exon 4 of IDH1 gene and exon 4 of IDH2 gene
Test 173.
Large deletions/ insertions and rearrangements in chromosome 1p/19q
Test 174.
large deletins/duplications rearrangements PDGFRA, EGFR, CDKN2A, PTEN, CDK4, MIR26A2, MDM2, NFKBIA and TP53 genes
Diagnostic markers for tumors in the central nervous system, endometrium, stomach, etc.
Test 175.
Mutations in ATRX gene
Test 176.
Large deletins/insertions in ATRX gene
Diagnostic and prognostic markers in brain, PNET, thyroid and other tumors
Test 177.
Mutation in promoter region of TERT gene
Test 178.
Mutations in exon 2 of H3F3A gene
Test 179.
Mutations in exon 1 of HIST1H3B and HIST1H3C genes.
Diagnostic marker for the presence of DICER1 syndrome
Diagnostic and Predictive Markers for Targeted Therapy in Gastrointestinal Stromal Tumor (GIST)
Test 181.
Mutations in exons 8, 9, 11, 13, 14, 17 and 18 of сKIT gene
Test 182.
Mutations in exons 12, 14 и 18 of PDGFRA gene
Test 183.
Mutations in exons 9 and 11 of сKIT gene, and mutations in exon 18 of PDGFRA gene
Test 184.
Mutations in exons 8, 13, 14, 17 and 18 of сKIT gene, exons 12 and 14 of PDGFRA gene and exon 15 of BRAF gene
Predictive marker BRAF (V600) mutations for targeted therapy in oncological diseases (melanoma, colorectal and lung carcinomas, thyroid gland, GIST, brain tumors, etc.)
Test 185.
Mutations in exon 15 of BRAF gene
Predictive marker for targeted therapy in chronic lymphocytic leukemia/CLL/
Test 186.
Mutations in TP53 gene
Test 187.
Анализ на TP53 гена, WES
Test 188.
Duplications/ deletions of 17p13 (TP53 gene), 13q14 (RB1/DLEU/MIR15A-region), 11q22 (ATM, trisomy 12)
Melanoma / predictive markers for targeted therapy
Chronic lymphocytic leukemia / CLL / predictive marker for targeted therapy
Optimization of the therapy with the indirect anticoagulant acenocoumarol (Syntrome)
Test 189.
3 polymorphisms in CYP2C9 and VKORC1 genes (CYP2C92, CYP2C93, VKORC1-1639G>A)
Optimization of platelet antiplatelet therapy clopidogrel (Plavix)
Test 190.
2 polymorphisms in CYP2C9 gene (CYP2C19*2, CYP2C19*17)
Optimization of methotrexate therapy
Optimization of therapy with the anti-tuberculosis drug isoniazid in pulmonary tuberculosis
Test 192.
7 polymorphisms in NAT2 gene
Investigation of DPYD variants to optimize chemotherapy with 5-fluorouracil and capecitabine
Test 193.
Variants DPYD∗2A, DPYD∗13, c.2846A>T, and c.1236G>A.
Изследване на UGT1A1 вариант за оптимизиране на химиотерапията
Test 194.
Анализ на 1 полиморфен вариант-повтор в промоторния участък на UGT1A1 гена
Minimal residual disease in patients with neuroblastoma
Test 195.
Panel of two (TH and PHOX2B) expression markers in patients with Neuroblastoma
Optimizing therapy with drugs from the thiopurine group (Azathioprine, Mercaptopurine and Thioguanine)
Test 196.
17 variants in the gene TPMT (TPMT *2, TPMT *3A, TPMT *3B, TPMT *3C, TPMT *3D, TPMT *4, TPMT* 6, TPMT *8, TPMT *9, TPMT*10, TPMT *11, TPMT *12, TPMT *13, TPMT *16, TPMT *17, TPMT *18, TPMT *24)
Test 197.
18 variants in NUDT15 gene (NUDT15 *2, NUDT15 *3, NUDT15*4, NUDT15*5, NUDT15*6, NUDT15*7, NUDT15*8, NUDT15*9, NUDT15*10, NUDT15*11-NUDT15*19)
Slow metabolizers by CYP2C9
Slow metabolizers by CYP2C19
Test 199.
CYP2C19*2 ( rs4244285, c.681 G>A) CYP2C19*3 ( rs4986893, c.636G > A)
Slow metabolizers by CYP2D6
Test 200.
CYP2D6*3 ( rs35742686, 2550 Del A) CYP2D6*4 ( rs3892097, 1846G > A)
Diagnostic markers in brain, rhabdoid, solid and other tumors
Test 202.
Deletions/duplications in region 22q11.21-q12.2, including TBX1, DGCR8, SNAP29, LZTR1, PPIL2, GNAZ, SMARCB1(INI1), SNRPD3, SEZ6L, NIPSNAP1 genes
Carrier Analysis of Variants Associated with Reproductive Disadvantages
Test 163.
Variants in BMP15 gene
Test 164.
Variants rs6165 and rs6166 in exon 10 of FSHR gene
Extended gene panel analysis for familial oncological diseases and interpretation
Test 203.
Mutations in 233 genes associated with oncology diseases
Analysis of a panel of genes associated with targeted therapy in solid tumors and interpretation
Whole Exome Sequencing (WES) and interpretation of the clinical exome
Test 204.
Mutations in 5227 genes associated with hereditary diseases
Whole Exome Sequencing (WES) without analysis and interpretation
Test 205.
Sequencing of 19 396 RefSeq genes. Read depth: mean coverage >= 50X, guaranteed 85% of bases with quality score >=Q30
Carrier testing in a family with a known genetic cause of hereditary disease
Test 206.
Analysis of SINGLE gene mutation in 1 relative
Confirmation analysis of Next Generation Sequencing Gene Mutation (NGS)
Test 207.
Confirmation Analysis of SINGLE Gene mutation after Next Generation Sequencing (NGS)
Confirmatory analysis / segregation of a CNV variant identified by next-generation sequencing (NGS)
Test 208.
Конкретни делеции/дупликации, пренареждания в различни части на генома, открити при секвениране от ново поколение (NGS) с микрочип
Confirmatory analysis / segregation of aberrations identified by microarray analysis and NGS
Test 209.
Делеции/дупликации пренареждания в известни геномни райони
Confirmatory analysis / segregation of a CNV variant identified by next-generation sequencing (NGS)
Test 210.
Делеции/дупликации пренареждания в известни геномни райони
Microdeletion / microduplication syndromes
Test 211.
Microarray analysis with SurePrint G3 Unrestricted CGH 4x180K, ISCA v2
Neurodevelopmental disorders/Autism spectrum disorders
Test 212.
Microarray analysis with SurePrint G3 Unrestricted CGH 4x180K, ISCA v2
Congenital anomalies and malformative syndromes / miscarriages
Test 213.
Microarray analysis with Unrestricted HD-CGH array ISCA v2, 4x44K
Confirmaton analysis / segregation of aberrations detected by microarray analysis
Prader Willi/Angelman syndromes
Test 214.
Large deletions/ insertions and rearrangements and methylation profile in genome region 15q11- PWS/AS
Russell-Silver/Beckwith-Wiedemann syndromes
Test 215.
Large deletions/ insertions and rearrangements and methylation profile in genome region 11p15BWS/RSS
Angelman syndromes
Uniparental disomy testing
DNA banking
Sequencing at the customer's request
Fragment analysis at the customer's request
Test 227.
1 sample for 1 microsatellite marker and customer's primers
Test 228.
1 sample for 24 microsatellites marker and customer's primers
Test 229.
1 sample for 96 microsatellite markers and customer's primers
Microarray scanning at the customer's request
Microarray scanning and bioinformatics analysis at the customer's request
Comprehensive bioinformatics analysis and interpretation of NGS data
Test 232.
Gene panel of 5 227 genes, associated with inhereted diseases
Test 233.
Whole exome - 19 396 RefSeq genes. Read depth - average coverage >=50X, guaranteed >= 85%bases with quality score >=Q30
Genetic counseling, Professor
Test 234.
Clinical interpretation and result, prepared and signed by a medical genetics specialist
Genetic counseling, Medical doctor
Test 235.
Clinical interpretation and result, prepared and signed by a medical genetics specialist
Microarray analysis with reagents provided by the Ministry of Health
Clinical exome analysis, confirmation and interpretation, with reagents provided by the Ministry of Health
Whole genome sequencing (WGS) with analysis and interpretation
Congenital adrenal hyperplasia (21 hydroxylase deficiency)
Neurofibromatosis type 1
Test 240.
Analysis of the NF1 gene for large deletions / insertions and rearrangements
Neurofibromatosis type 2
Test 241.
Analysis of the NF2 gene for large deletions / insertions and rearrangements
Growth deficiency
Chromosomal copy number changes in childhood solid tumors (Neublastoma / rhabdomyosarcoma / Ewing's sarcoma / Wilm's tumor) with reagents provided by the Ministry of Health
Test 243.
MYCN Amplification Study, Chromosome Aberrations 1, 2, 3, 4, 7, 9, 11, 12, 14, 17
Pediatric solid tumors
Test 244.
Анализ и интерпретация на соматични варианти в панел от гени, свързани с детски солидни тумори
Whole genome sequencing (WGS) with analysis and interpretation of a panel of up to 100 genes
Test 245.
Секвениране на >20 000 RefSeq ядрени гени, включително SNVs, InDels,SVs, CNVs. Дълбочина на четене: средно покритие ≥30X, гарантирани ≥ 97% на бази с качество ≥Q10; анализ и интерпретация на панел от до 100 гени, свързани с конкретното заболяване
Whole genome sequencing (WGS) with analysis and interpretation of a panel of 100 to 200 genes
Test 246.
Секвениране на >20 000 RefSeq ядрени гени, включително SNVs, InDels,SVs, CNVs. Дълбочина на четене: средно покритие ≥30X, гарантирани ≥ 97% на бази с качество ≥Q10; анализ и интерпретация на панел от 100 до 200 гени, свързани с конкретното заболяване
Whole genome sequencing (WGS) with analysis and interpretation of a panel of 200 to 500 genes
Test 247.
Секвениране на >20 000 RefSeq ядрени гени,включително SNVs, InDels,SVs, CNVs. Дълбочина на четене: средно покритие ≥30X, гарантирани ≥ 97% на бази с качество ≥Q10; анализ и интерпретация на панел от 200 до 500 гени, свързани с конкретното заболяване
Whole genome sequencing (WGS) with analysis and interpretation of a panel of over 500 genes
Bioinformatic analysis and interpretation of whole genome sequencing (WGS) data
Test 249.
Анализ и интерпретация на данни от Цялостно геномно секвениране (WGS), включващ екзомен панел от всички известни гени, асоциирани с наследствени заболявания
Test 250.
Анализ и интерпретация на данни от Цялостно геномно секвениране (WGS), включващ SNVs, InDels,SVs, CNVs, асоциирани с наследствени заболявания